Response of biochemical markers of bone turnover to oral glucose load in diseases that affect bone metabolism

European Journal of Endocrinology

Volumn 164, Issue 6, 2011, Pages 1035-1041

  Yavropoulou, Maria P ^a   Tomos, Konstantinos ^a   Tsekmekidou, Xanthippi ^a   Anastasiou, Olympia ^a   Zebekakis, Pantelis ^a   Karamouzis, Michael ^a   Gotzamani Psarrakou, Anna ^a   Chassapopoulou, Eleni ^a   Chalkia, Panagiota ^a   Yovos, John G ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; GLUCOSE; OSTEOCALCIN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; BETA CARBOXY TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BETA THALASSEMIA; BONE TURNOVER; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OSTEOLYSIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BODY MASS; CONCENTRATION (PARAMETERS); PATHOGENESIS; PROTEIN DETERMINATION;

BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE AND BONES; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; COLLAGEN TYPE I; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MIDDLE AGED; OSTEOCALCIN; PROCOLLAGEN;

EID: 79957717049     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0128     Document Type: Article

References (34)

1. Wichers M, Schmidt E, Bidlingmaier F & Klingmuller D. Diurnal rhythm of CrossLaps in human serum. Clinical Chemistry 1999 45 1858-1860. (Pubitemid 29477347)
2. Pietschmann P, Resch H, Woloszczuk W & Willvonseder R. A circadian rhythm of serum osteocalcin levels in postmenopausal osteoporosis. European Journal of Clinical Investigation 1990 20 310-312. (doi:10.1111/j.1365-2362. 1990.tb01861.x)
3. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsbøll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ & Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. Journal of Bone and Mineral Research 2003 18 2180-2189. (doi:10.1359/jbmr.2003.18.12. 2180)
4. Chailurkit LO, Chanprasertyothin S, Rajatanavin R & Ongphiphadhanakul B. Reduced attenuation of bone resorption after oral glucose in type 2 diabetes. Clinical Endocrinology 2008 68 858-862. (doi:10.1111/j.1365-2265.2007. 03159.x)
5. Gogakos AI, Duncan Bassett JH & Williams GR. Thyroid and bone. Archives of Biochemistry and Biophysics 2010 503 129-136. (doi:10.1016/j.abb. 2010.06.021)
6. Mazziotti G, Porcelli T, Patelli I, Vescovi PP & Giustina A. Serum TSH values and risk of vertebral fractures in euthyroid postmenopausal women with low bone mineral density. Bone 2010 46 747-751. (doi:10.1016/j.bone.2009. 10.031)
7. Murphy E, Gluer CC, Reid DM, Felsenberg D, Roux C, Eastell R & Williams GR. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2010 95 3173-3181. (doi:10.1210/jc.2009-2630)
8. Vestergaard P & Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002 12 411-419. (doi:10.1089/105072502760043503)
9. Vestergaard P & Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 2003 13 585-593. (doi:10.1089/ 105072503322238854)
10. Bauer DC, Ettinger B, Nevitt MC & Stone KL. Risk for fracture in women with low serum levels of thyroid stimulating hormone. Annals of Internal Medicine 2001 134 561-568. (Pubitemid 32245317)
11. Beber EH, Capelo LP, Fonseca TL, Costa CC, Lotfi CF, Scanlan TS & Gouveia CH. The thyroid hormone receptor (TR) β-selective agonist GC-1 inhibits proliferation but induces differentiation and TRβ mRNA expression in mouse and rat osteoblast-like cells. Calcified Tissue International 2009 84 324-333. (doi:10.1007/s00223-009-9230-1)
12. 3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcified Tissue International 2004 74 382-387. (doi:10.1007/s00223-003-0033-5)
13. Britto JM, Fenton AJ, Holloway WR & Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994 134 169-176. (doi:10.1210/en.134.1.169)
14. Higgs DR, Thein SL & Wood WG. The biology of thalassaemias. In The thalassaemia syndromes. Edn 4, Chapter 3, pp 121-132. Eds DJWeatherall & JB Clegg. Oxford: Blackwell Science Ltd 2001.
15. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV & Wonke B. High prevalence of low bone mass in thalassaemia major. British Journal of Haematology 1998 103 911-915. (doi:10.1046/j.1365- 2141.1998.01108.x)
16. Vichinsky EP. The morbidity of bone disease in thalassemia. Annals of the New York Academy of Sciences 1998 850 344-348. (doi:10.1111/j.1749-6632.1998. tb10491.x)
17. Haidar R, Musallam KM & Taher AT. Bone disease and skeletal complications in patients with β thalassemia major. Bone 2011 48 425-432. (doi:10.1016/j.bone.2010.10.173)
18. Voskaridou E & Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. British Journal of Haematology 2004 127 127-139. (doi:10.1111/j.1365-2141.2004.05143.x)
19. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R & Rajatanavin R. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. Journal of Clinical Endocrinology and Metabolism 2003 88 3966-3972. (doi:10.1210/jc.2002- 021548)
20. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A & Loukopoulos D. Bone resorption is increased in young adults with thalassaemia major. British Journal of Haematology 2001 112 36-41. (doi:10.1046/j.1365-2141.2001.02549.x)
21. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Malaktari S, Athanasiou V & Tolis G. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. Journal of Bone and Mineral Metabolism 2007 25 60-67. (doi:10.1007/s00774-006-0728-6)
22. Bernstein CN & Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. European Journal of Gastroenterology and Hepatology 2003 15 857-864. (doi:10.1097/00042737-200308000-00004)
23. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 2002 30 5-7. (doi:10.1016/S8756-3282(01)00642-1)
24. Vestergaard P, Rejnmark L & Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcified Tissue International 2005 77 139-144. (doi:10.1007/s00223-005-0068-x)
25. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A & Frisina N. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. Journal of Bone and Mineral Research 2004 19 722-727. (doi:10.1359/jbmr.040113)
26. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Konstandelou E & Tolis G. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Journal of Pediatric Hematology/Oncology 2007 24 481-489.
27. Lian JB, Stein JL, Stein GS, Montecino M, van Wijnen AJ, Javed A & Gutierrez S. Contributions of nuclear architecture and chromatin to vitamin D-dependent transcriptional control of the rat osteocalcin gene. Steroids 2001 66 159-170. (doi:10.1016/S0039-128X(00)00160-4)
28. Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB & Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006 38 888-892. (doi:10.1016/j.bone.2005.11.018)
29. Stamato FJ, Amarante EC & Furlanetto RP. Effect of combined treatment with calcitonin on bone densitometry of patients with treated hypothyroidism. Revista da Associação Médica Brasileira 2000 46 177-181. (doi:10.1590/S0104-42302000000200013)
30. Mosekilde L, Eriksen EF & Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinology and Metabolism Clinics of North America 1990 19 35-63. (Pubitemid 20142107)
31. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V & Joakimsen RM. Self-reported diseases and the risk of non-vertebral fractures: the Tromsø study. Osteoporosis International 2006 17 46-53. (doi:10.1007/s00198-005-1892-6)
32. Ebert EC. The thyroid and the gut. Journal of Clinical Gastroenterology 2010 44 402-406. (doi:10.1097/MCG.0b013e3181d6bc3e)
33. Doong ML, Wang JW, Chung SC, Liu JY, Hwang C, Hwang CY, Day CH, Liu YF, Young TK, Ho LL & Wang PS. Regulation of thyroid hormones in the secretion of insulin and gastric inhibitory polypeptide in male rats. Metabolism 1997 46 154-158. (doi:10.1016/S0026-0495(97)90294-8)
34. Hays JH, Silverman E, Potter BB & Shakir KM. Normal gastric inhibitory polypeptide response to oral glucose in hypothyroidism. Journal of Endocrinology 1994 140 309-312. (doi:10.1677/joe.0.1400309)